Turkey: These 9 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Turkey
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Turkey: These 9 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can HUMALOG KWIKPEN (insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
HUMALOG KWIKPEN is a drug marketed by There has been litigation on patents covering HUMALOG KWIKPEN
See drug price trends for HUMALOG KWIKPEN.
The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this API. Additional details are available on the insulin lispro recombinant profile page.
When can HUMALOG MIX 50/50 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
HUMALOG MIX 50/50 KWIKPEN is a drug marketed by There has been litigation on patents covering HUMALOG MIX 50/50 KWIKPEN
The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMALOG MIX 75/25 KWIKPEN (insulin lispro protamine recombinant; insulin lispro recombinant) generic drug versions launch?
Generic name: insulin lispro protamine recombinant; insulin lispro recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
HUMALOG MIX 75/25 KWIKPEN is a drug marketed by There has been litigation on patents covering HUMALOG MIX 75/25 KWIKPEN
The generic ingredient in HUMALOG MIX 75/25 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this API. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
When can HUMULIN 70/30 (insulin recombinant human; insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin recombinant human; insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
HUMULIN 70/30 is a drug marketed by There has been litigation on patents covering HUMULIN 70/30
The generic ingredient in HUMULIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this API. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
When can HUMULIN N (insulin susp isophane recombinant human) generic drug versions launch?
Generic name: insulin susp isophane recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
See drug price trends for HUMULIN N.
The generic ingredient in HUMULIN N is insulin susp isophane recombinant human. There are forty drug master file entries for this API. Additional details are available on the insulin susp isophane recombinant human profile page.
When can HUMULIN R (insulin human) generic drug versions launch?
Generic name: insulin human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2023
Generic Entry Controlled by: Turkey Patent 201,903,984
See drug price trends for HUMULIN R.
The generic ingredient in HUMULIN R is insulin human. There are forty drug master file entries for this API. Additional details are available on the insulin human profile page.
When can SAXENDA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Turkey Patent 201,906,789
This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA
See drug price trends for SAXENDA.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can VICTOZA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Turkey Patent 201,906,789
This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA
See drug price trends for VICTOZA.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can CHILDREN'S ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) generic drug versions launch?
Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: Turkey Patent 200,501,948
Patent Title: Farmasötik süspansiyon bileşimi.
CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.
This drug has nine patent family members in eight countries.
The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
